Our Firm is representing numerous plaintiffs in Risperdal lawsuits that put forth similar allegations regarding the methods use to market the medication.
New York, New York (PRWEB) March 03, 2015
Risperdal lawsuits (http://www.risperdallawsuit2014.com/) that question tactics used to market the atypical antipsychotic medication continue to move forward in courts around the U.S. According to court documents, the South Carolina Supreme Court upheld a state court jury’s 2011 finding that Johnson & Johnson’s Janssen Pharmaceuticals unit had deceptively marketed the medication and concealed its serious risks. However, while the Court’s February 25th decision characterized the company’s conduct as an “egregious violation of South Carolina law,” it did reduce the jury’s original $327 million judgment, and ordered Janssen to pay $136 million penalty. (State of South Carolina v. Ortho-McNeil-Janssen Pharmaceuticals Inc, No. 2012-206987)
“In reducing the jury’s original judgment, the Court cited a three-year limit for bringing certain claims under South Carolina’s Unfair Trade Practices Act. Our Firm is representing numerous plaintiffs in Risperdal lawsuits that put forth similar allegations regarding the methods use to market the medication, and we are pleased that the jury’s finding regarding the drug maker’s conduct in this case was upheld,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide legal consultations to men and boys who allegedly experienced gynecomastia, or male breast growth, due to their use of Risperdal.
Court records indicate that the South Carolina Supreme Court rendered its decision just one day after a Pennsylvania jury ordered Johnson & Johnson and Janssen to pay $2.5 million in compensatory damages to an autistic man who developed gynecomastia due to his use of the medication as a child. (Case No. A-196444) The case was the first bellwether trial to involve Risperdal and male breast growth in mass tort litigation, where Bernstein Liebhard LLP is actively filing claims. All of the Risperdal lawsuits pending in Pennsylvania were brought on behalf of individuals who where allegedly harmed by the drug, and like the South Carolina case, accuse the manufacturers of Risperdal of improperly marketing the medication and concealing its association with serious complications. (In Re: Risperdal Litigation, Case Number 100300296)
Victims of gynecomastia allegedly related to the use of Risperdal may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com